A meta-analysis of gene expression profiles identified three robust HCC subclasses (termed S1, S2, and S3), characterized by an aberrant activation of the TGF-β and Wnt/β-catenin signaling pathways (S1), Myc and Akt activation, as well as down-regulation of IFN-target genes (S2), and activation of p53 and p21 target genes, and genes associated with hepatocyte differentiation (S3) [4]. The gene discussed is TP53; the disease is hepatocellular carcinoma.